Preclinical efficacy of dual mTORC1/2 inhibitor AZD8055 in renal cell carcinoma harboring a TFE3 gene fusion.

In both xenograft models, this tumor volume reduction with sirolimus did not reach statistical significance relative to the corresponding vehicle control (UOK146: p = 0.315; UOK120: p = 0.691) and was of significantly lower magnitude compared to the reduction achieved with AZD8055 (UOK146: p = 0.0003; UOK120: p = 0.004).

also in 111,027 other papers